Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 11/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL1487682 | 1.00 | SLC7A5 (0.43) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL15641588 | 1.00 | SLC7A5 (0.43) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL1255583 | 0.87 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8868 | 0.87 | — | — | |
| Isoleucine SCHEMBL1147268 | 0.87 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8186739 | 0.87 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL20340795 | 0.87 | — | — | |
| Isoleucine SCHEMBL8045737 | 0.87 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8043620 | 0.87 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL1255582 | 0.87 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448357-B1 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2025-10-21 | — | — | US | claimed |
| US-11155524-B2 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | claimed |
| US-20200297678-A1 | Amino Acid Compositions | THERMOLIFE INTERNATIONAL, LLC | 2020-09-24 | — | — | US | claimed |
| CN-101817757-B | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | claimed |
| CN-101817757-A | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2010-09-01 | — | — | CN | claimed |
| US-20260115150-A1 | FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME | NUTRITION21 LLC (US) | 2026-04-30 | — | — | US | disclosed |
| CN-119980515-A | Method for preparing chitosan fiber from amino acid ionic liquid aqueous solution | 郑州中科新兴产业技术研究院 | 2025-05-13 | — | — | CN | disclosed |
| US-11155524-B2 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155524-B2 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200297678-A1 | Amino Acid Compositions | THERMOLIFE INTERNATIONAL, LLC | 2020-09-24 | — | — | US | disclosed |
| US-20200297678-A1 | Amino Acid Compositions | THERMOLIFE INTERNATIONAL, LLC | 2020-09-24 | — | — | US | disclosed |
| US-8703719-B1 | Method and composition for improved muscle performance | BIO-ENGINEERED SUPPLEMENTS AND NUTRITION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101817757-B | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-101817757-B | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-101817757-B | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | disclosed |
| US-20110064720-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | AMATO DANIEL MOSES | 2011-03-17 | — | — | US | disclosed |
| US-20110064712-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | AMATO DANIEL MOSES | 2011-03-17 | — | — | US | disclosed |
| CN-101817757-A | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2010-09-01 | — | — | CN | disclosed |
| CN-101817757-A | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2010-09-01 | — | — | CN | disclosed |
| CN-101817757-A | Preparation method of L-isoleucine nitrate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2010-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448357-B1 | Amino acid compositions | SLC6A15, SLC1A5, SLC6A19 | SLC7A5 13/4885DPP4 1528/4885DPP8 1258/4885 |
| US-20110064720-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | SLC5A6, PNLIP, LIPC | SLC7A5 1489/4885DPP4 2759/4885DPP8 1501/4885 |
| US-20110064712-A1 | Dietary Supplement Compositions and Methods of Making and Using the Same | SLC5A6, PNLIP, LIPC | SLC7A5 1489/4885DPP4 2759/4885DPP8 1501/4885 |
| US-20200297678-A1 | Amino Acid Compositions | ASNS, ARGLU1, SLC6A15 | SLC7A5 27/4885DPP4 2872/4885DPP8 2537/4885 |
| US-20260115150-A1 | FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME | CUTA, NOS1, NOS2 | SLC7A5 51/4885DPP4 4536/4885DPP8 4564/4885 |
| US-11155524-B2 | Amino acid compositions | ASNS, ARGLU1, SLC6A15 | SLC7A5 27/4885DPP4 2872/4885DPP8 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.